GBNH(GBNH)

$0.12—Stale · unknown old

GBNH(GBNH)

NASDAQ • Last print unknown ago

$0.12—Stale · unknown old

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

8/30/26

Greenbrook TMS (GBNH)

Sunday

12:36 PM

ThesisThe company is facing significant operational challenges and competitive pressures that may hinder revenue growth.

Revenue Outlook

Metric	FY2022	FY2023E	FY2024E
Revenue	$69M	$79M	$100M
Rev. Growth	+32.4%	+14.9%	+25.7%
EPS	$-3.73	$-1.37	$-0.52
EPS Growth	-95.3%	+63.3%	+62.0%
P/E	—	—	—

★ Analysts see FY2024 revenue reaching $100M — +25.7% growth in a single year.

What Moves the Stock

01Changes in reimbursement policies for TMS therapy
02Expansion of clinic locations in high-demand areas
03Patient volume growth driven by increased awareness of mental health treatments
04Regulatory changes affecting mental health treatment protocols
05TMS therapy sessions - 80%
06Consultation services - 15%
07Other mental health services - 5%
08Growing acceptance of mental health treatment in mainstream healthcare

FY2022 Snapshot

Revenue: $69M
Rev. Growth: +32.4%
Gross Margin: 8.8%
Op. Margin: -42.6%
Net Margin: -125%
Net Income: $-87M
NI Growth: -194%
EPS: $-3.73

GBNH Chart

No chart data

My Notes

"Management noted, 'We are navigating a challenging landscape with increasing competition and regulatory pressures.'"
Moat: The company's established network and proprietary treatment protocols provide a moderate level of competitive advantage.
growth - Investors interested in expanding mental health markets and innovative treatment solutions.
Minimal impact as the company primarily relies on cash flows from operations rather than debt financing.
Watch on earnings: Number of TMS therapy sessions conducted, Patient acquisition costs, Revenue growth rate.

One Sentence Summary:

Greenbrook TMS: the story is balanced — changes in reimbursement policies for tms therapy.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.